Journal
NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 18, Issue 12, Pages 1336-U48Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb.2142
Keywords
-
Funding
- Hastings Foundation
- Fletcher Jones Foundation
- William Lawrence and Blanche Hughes (WLBH) Foundation
- National Research Foundation of Korea [K20815000001, NRF-M1AXA002-2010-0029767]
- 21C Frontier Microbial Genomics and Applications Center
- Ministry of Education, Science and Technology, Korea
- [CA82057]
- [CA31363]
- [CA115284]
- [CA147868]
- [CA148616]
- [DE019085]
- Medical Research Council [G0501453] Funding Source: researchfish
- MRC [G0501453] Funding Source: UKRI
Ask authors/readers for more resources
Herpesvirus-associated ubiquitin-specific protease (HAUSP) regulates the stability of p53 and the p53-binding protein MDM2, implicating HAUSP as a therapeutic target for tuning p53-mediated antitumor activity. Here we report the structural analysis of HAUSP with Kaposi's sarcoma-associated herpesvirus viral interferon (IFN) regulatory factor 4 (vIRF4) and the discovery of two vIRF4-derived peptides, vif1 and vif2, as potent and selective HAUSP antagonists. This analysis reveals a bilateral belt-type interaction that results in inhibition of HAUSP. The vif1 peptide binds the HAUSP TRAF domain, competitively blocking substrate binding, whereas the vif2 peptide binds both the HAUSP TRAF and catalytic domains, robustly suppressing its deubiquitination activity. Peptide treatments comprehensively blocked HAUSP, leading to p53-dependent cell-cycle arrest and apoptosis in culture and to tumor regression in xenograft mouse model. Thus, the virus has developed a unique strategy to target the HAUSP-MDM2-p53 pathway, and these virus-derived short peptides represent biologically active HAUSP antagonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available